Fintel reports that on March 10, 2026, William Blair initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform recommendation.
Analyst Price Forecast Suggests 33.36% Upside
As of February 25, 2026, the average one-year price target for BridgeBio Pharma is $99.16/share. The forecasts range from a low of $68.11 to a high of $164.85. The average price target represents an increase of 33.36% from its latest reported closing price of $74.35 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BridgeBio Pharma is 586MM, an increase of 16.77%. The projected annual non-GAAP EPS is -3.15.
What is the Fund Sentiment?
There are 544 funds or institutions reporting positions in BridgeBio Pharma. This is an decrease of 205 owner(s) or 27.37% in the last quarter. Average portfolio weight of all funds dedicated to BBIO is 0.41%, an increase of 1.12%. Total shares owned by institutions decreased in the last three months by 9.74% to 194,364K shares. 
The put/call ratio of BBIO is 0.70, indicating a bullish outlook.
What are Other Shareholders Doing?
Viking Global Investors holds 14,394K shares representing 7.42% ownership of the company. In its prior filing, the firm reported owning 15,978K shares , representing a decrease of 11.00%. The firm increased its portfolio allocation in BBIO by 35.58% over the last quarter.
Kohlberg Kravis Roberts & Co. holds 13,261K shares representing 6.84% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 11,000K shares representing 5.67% ownership of the company. In its prior filing, the firm reported owning 8,741K shares , representing an increase of 20.54%. The firm increased its portfolio allocation in BBIO by 72.20% over the last quarter.
Farallon Capital Management holds 8,998K shares representing 4.64% ownership of the company. In its prior filing, the firm reported owning 8,192K shares , representing an increase of 8.96%. The firm increased its portfolio allocation in BBIO by 86.47% over the last quarter.
Aisling Capital Management holds 5,090K shares representing 2.63% ownership of the company. In its prior filing, the firm reported owning 6,090K shares , representing a decrease of 19.65%. The firm increased its portfolio allocation in BBIO by 17.31% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
